# HTT (Huntingtin): CAG Trinucleotide Repeat Expansion, Polyglutamine Aggregation, and Neurodegeneration


## Key Takeaways

- Pathogenic expansion of the CAG trinucleotide repeat in exon 1 of the *HTT* gene, exceeding approximately 35 units, leads to Huntington's disease (HD). This expansion results in an abnormally long polyglutamine (polyQ) tract at the N-terminus of the huntingtin protein, conferring a toxic gain-of-function through misfolding and aggregation, alongside a partial loss-of-function in normal cellular processes.
- The huntingtin protein (HTT) is a large scaffolding protein essential for embryonic development, vesicular trafficking, autophagy, and transcriptional regulation, with ubiquitous expression highest in the striatum and cortex. Its structure comprises tandem HEAT repeats, with the N-terminal domain (NTD) being critical as it harbors the polyQ tract and is the primary site for proteolytic cleavage generating toxic fragments.
- HTT plays a crucial role in cellular signaling pathways, including coordinating vesicular transport via interactions with dynein and kinesin, acting as an autophagy receptor through its LC3-interacting region (LIR), and regulating gene expression by sequestering transcription factors like REST. PolyQ expansion disrupts these functions, leading to impaired axonal transport, autophagic stress, and altered gene transcription.
- The CAG repeat length directly correlates with disease onset and severity; alleles of 40 or more units are fully penetrant, while lengths of 36-39 units confer reduced penetrance. Somatic instability of the CAG repeat, particularly in the striatum, further influences disease progression and is modulated by DNA mismatch repair pathways such as MutSβ (MSH2-MSH3).
- Current therapeutic strategies focus on reducing mutant HTT levels, including investigational antisense oligonucleotides (ASOs) like tominersen and allele-specific ASOs, as well as small-molecule splicing modulators such as branaplam. Symptomatic treatment for chorea is primarily managed with VMAT2 inhibitors like deutetrabenazine.

---

## Executive Summary & Key Metadata

The *HTT* gene encodes huntingtin (HTT), a large, ubiquitously expressed scaffolding protein of 3,144 amino acids (≈348 kDa) that is essential for embryonic development, vesicular trafficking, autophagy, and transcriptional regulation. Pathogenic expansion of a CAG trinucleotide repeat in exon 1 beyond ~35 units translates into an expanded polyglutamine (polyQ) tract at the N-terminus of the protein. This expansion confers a toxic gain-of-function through misfolding, proteolytic cleavage, and aggregation, while simultaneously causing a partial loss-of-function in normal HTT-mediated cellular processes. The resulting autosomal dominant disorder, Huntington's disease (HD), is characterized by progressive chorea, cognitive decline, and psychiatric disturbances, with selective neurodegeneration of the striatum and cortex.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | HTT |
| UniProt Accession | P42858 |
| Representative PDB ID | 6EZ4 (N-terminal domain, residues 1–171) |
| Chromosomal Locus | 4p16.3 |
| Primary Molecular Function | Scaffold protein; vesicular trafficking; autophagy; transcriptional regulation; anti-apoptotic |
| Disease & Pathology Associations | Huntington's disease (OMIM #143100); CAG repeat expansion disorders; somatic instability |
| Expression Pattern | Ubiquitous; highest in brain (striatum, cortex, cerebellum) |
| Subcellular Localization | Cytoplasm, nucleus, mitochondria, endosomes, autophagosomes, ER |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Gene Coordinates and Architecture

The *HTT* gene is located on the short arm of chromosome 4 at cytogenetic band 4p16.3. In the GRCh38/hg38 assembly, *HTT* spans approximately 180 kilobases (kb) of genomic DNA, from position 3,074,681 to 3,254,429 on the forward strand. The gene contains 67 exons, with the first exon being the most clinically significant due to the presence of the CAG repeat tract. The canonical transcript (ENST00000229002.11) is 13,710 nucleotides in length, encoding the full-length 3,144-amino-acid huntingtin protein.

The 5' untranslated region (UTR) is relatively short (~200 bp) and contains a CpG island that is subject to differential methylation. The promoter region lacks a canonical TATA box but contains multiple Sp1 and E-box binding sites, allowing for constitutive, housekeeping-level expression across all tissues. The 3' UTR is unusually long (~3.5 kb) and contains multiple AU-rich elements (AREs) that regulate mRNA stability in response to cellular stress.

### 1.2 Promoter Architecture and Transcription Factor Binding

The *HTT* promoter is characterized by a GC-rich region spanning approximately 1.2 kb upstream of the transcription start site (TSS). Key transcription factor binding sites include:

- **Sp1/Sp3**: Bind to GC-boxes and drive basal transcription. Sp1 binding is enhanced by histone acetylation, linking *HTT* expression to chromatin remodeling.
- **NF-κB**: A binding site at −450 bp mediates inflammatory and stress-induced upregulation of HTT.
- **CREB/ATF**: A cAMP response element (CRE) at −280 bp allows for activity-dependent transcriptional regulation in neurons.
- **E-box elements**: Bound by basic helix-loop-helix (bHLH) factors such as USF1 and USF2, contributing to cell-cycle-dependent expression.

Enhancer elements have been identified in intron 1 and intron 3 via chromatin conformation capture (Hi-C) studies. These enhancers interact with the promoter in a tissue-specific manner, with the strongest interactions observed in striatal medium spiny neurons (MSNs), the primary cell type affected in HD.

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of *HTT* produces multiple isoforms with distinct functional properties:

| **Isoform** | **Exons Included** | **Molecular Weight** | **Functional Significance** |
|---|---|---|---|
| Full-length HTT | 1–67 | 348 kDa | Canonical protein; predominant in brain |
| HTT Δexon1/2 | Exons 3–67 | ~340 kDa | Lacks polyQ tract; may act as dominant-negative |
| HTT Δexon12 | Exons 1–11, 13–67 | ~340 kDa | Altered HEAT repeat spacing; reduced vesicle binding |
| HTT Δexon29/30 | Exons 1–28, 31–67 | ~340 kDa | Impaired autophagy receptor function |
| Short HTT (sHTT) | Exons 1–12 | ~60 kDa | Nuclear-localized; regulates transcription |

The most extensively studied splice variant is the N-terminal exon 1 fragment, which is produced not only by alternative splicing but also by aberrant splicing events that skip the intron 1 splice donor site. This exon 1-only transcript (encoding ~90 amino acids plus the polyQ tract) is highly toxic and is the primary species that aggregates in HD patient brains. The production of this fragment is enhanced by the presence of expanded CAG repeats, which promote aberrant splicing through a mechanism involving the splicing factor SRSF6.

### 1.4 CAG Repeat Tract and Somatic Instability

The CAG repeat tract is located in exon 1, beginning at codon 18 of the coding sequence. In the general population, the repeat length ranges from 6 to 35 units. Alleles of 36–39 units are considered "reduced penetrance," while alleles of 40 or more units are fully penetrant. The repeat is polymorphic and exhibits somatic instability, with the greatest expansion occurring in the striatum, the primary site of pathology. This somatic instability is driven by DNA mismatch repair (MMR) pathways, particularly MutSβ (MSH2-MSH3) and MutLγ (MLH1-MLH3), which promote expansion by stabilizing slipped-strand DNA structures during replication and repair.

The CAG repeat is immediately followed by a CAACAG cassette, which is sometimes included in repeat length measurements. The polyQ tract is encoded by the CAG repeat, with the adjacent CAA codon also encoding glutamine, resulting in a pure polyQ stretch of variable length.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Topology

Huntingtin is a largely α-helical protein composed of tandem arrays of HEAT (Huntingtin, Elongation factor 3, protein phosphatase 2A, TOR1) repeats. Each HEAT repeat consists of two antiparallel α-helices (helix A and helix B) connected by a short loop, forming a superhelical solenoid structure. The full-length protein contains approximately 36 HEAT repeats, organized into four major structural domains:

1. **N-terminal domain (NTD)**: Residues 1–171, containing the polyQ tract, a proline-rich region, and the first HEAT repeat.
2. **Bridge domain**: Residues 172–400, connecting the NTD to the main solenoid.
3. **Central solenoid**: Residues 401–2,700, composed of HEAT repeats 2–30, forming a crescent-shaped superhelix.
4. **C-terminal domain (CTD)**: Residues 2,701–3,144, containing HEAT repeats 31–36 and a nuclear export signal (NES).

### 2.2 N-Terminal Domain (Residues 1–171)

The N-terminal domain is the most structurally characterized region, with the crystal structure of residues 1–171 solved at 2.6 Å resolution (PDB: 6EZ4). This structure reveals:

- **PolyQ tract (residues 18–38 in normal HTT)**: Disordered in the crystal structure, consistent with its intrinsic flexibility. [Molecular dynamics simulations](/knowledge/bioinformatics/molecular-dynamics-simulations-of-proteins-and-force-fields) suggest that the polyQ tract adopts a heterogeneous ensemble of conformations, including random coil, α-helix, and β-turn structures.
- **Proline-rich region (residues 39–68)**: Contains multiple PXXP motifs that bind SH3 and WW domain-containing proteins, including the adaptor protein Grb2 and the ubiquitin ligase WWP1.
- **N-terminal α-helix (residues 1–17)**: Forms a short amphipathic helix that mediates membrane binding and is required for autophagosome formation.
- **HEAT repeat 1 (residues 69–171)**: The first canonical HEAT repeat, which packs against the proline-rich region and provides a platform for protein-protein interactions.

The NTD is the primary site of proteolytic cleavage by caspases (at Asp513) and calpains (at Arg167), generating toxic N-terminal fragments that translocate to the nucleus and nucleate aggregation.

### 2.3 HEAT Repeat Solenoid

The central solenoid forms a right-handed superhelix with a pitch of ~40 Å and a diameter of ~60 Å. The inner surface of the solenoid is lined with conserved hydrophobic residues that mediate interactions with partner proteins, while the outer surface is enriched in charged residues that interact with membranes and nucleic acids. The solenoid is punctuated by three "hinge" regions (residues 700–800, 1,400–1,500, and 2,100–2,200) that introduce kinks in the superhelix, allowing the protein to adopt multiple conformations.

Cryo-electron microscopy (cryo-EM) reconstructions of full-length HTT at ~4 Å resolution reveal that the protein forms a dimer in solution, with the two protomers associating through their C-terminal domains. The dimer interface is stabilized by a coiled-coil motif in the CTD, and dimerization is required for HTT's function in vesicle trafficking.

### 2.4 Post-Translational Modification Sites

Huntingtin is subject to extensive post-translational modification (PTM), with over 100 documented modification sites:

- **Phosphorylation**: Ser13 and Ser16 (by IKKβ and CDK5) regulate nuclear localization and toxicity; Ser421 (by Akt) promotes pro-survival signaling; Ser434 and Ser1181 (by CDK5) modulate vesicle trafficking.
- **Acetylation**: Lys444 (by CBP) promotes autophagy; deacetylation by SIRT1 enhances toxicity.
- **Ubiquitination**: Lys48-linked ubiquitination at multiple lysines targets HTT for proteasomal degradation; Lys63-linked ubiquitination at Lys6 and Lys9 promotes autophagic clearance.
- **SUMOylation**: Lys6, Lys9, and Lys15 are SUMOylated, competing with ubiquitination and stabilizing the protein.
- **Palmitoylation**: Cys214 is palmitoylated by HIP14, promoting membrane association.

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load HTT (PDB: 6EZ4)](/tools/protein-structure-viewer?source=direct&pdbId=6EZ4)

The visualizer tool allows users to explore the N-terminal domain structure in atomic detail, including the polyQ tract (modeled as a flexible loop), the proline-rich region, and the first HEAT repeat. Users can toggle between cartoon, surface, and electrostatic representations, and can highlight specific residues implicated in post-translational modifications.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Vesicular Trafficking and Axonal Transport

Huntingtin functions as a molecular scaffold that coordinates the trafficking of vesicles, organelles, and mRNA along microtubules and actin filaments. The protein interacts with:

- **Dynein/dynactin complex**: HTT binds to dynactin p150Glued via its N-terminal domain, facilitating retrograde transport of endosomes and autophagosomes.
- **Kinesin-1 (KIF5A)**: HTT interacts with kinesin light chain (KLC) through its central solenoid, promoting anterograde transport of synaptic vesicles and BDNF-containing vesicles.
- **Rab GTPases**: HTT binds to Rab5 and Rab11 via its C-terminal domain, regulating early endosome fusion and recycling endosome trafficking.
- **HAP1 (huntingtin-associated protein 1)**: HAP1 binds to HTT's N-terminal domain and links HTT to the p150Glued subunit of dynactin, enhancing processive movement along microtubules.

In the context of HD, the expanded polyQ tract impairs HTT's ability to bind to dynein and kinesin, leading to reduced axonal transport of BDNF and other neurotrophic factors. This transport deficit is particularly severe in striatal MSNs, which depend on cortical-derived BDNF for survival.

### 3.2 Autophagy and Proteostasis

HTT is a selective autophagy receptor that targets ubiquitinated cargo to autophagosomes. The protein contains an LIR (LC3-interacting region) motif at residues 1,292–1,295 (WYQL), which binds to LC3 on the autophagosome membrane. HTT also interacts with p62/SQSTM1 and NBR1, bridging ubiquitinated protein aggregates to the autophagic machinery.

The polyQ expansion disrupts HTT's autophagy receptor function in two ways:

1. **Impaired cargo recognition**: The expanded polyQ tract reduces HTT's affinity for ubiquitinated cargo, leading to accumulation of damaged mitochondria and protein aggregates.
2. **Defective autophagosome transport**: Mutant HTT impairs the trafficking of autophagosomes along axons, preventing their fusion with lysosomes and resulting in autophagic stress.

### 3.3 Transcriptional Regulation

HTT shuttles between the cytoplasm and nucleus, where it regulates gene expression through interactions with transcription factors and chromatin modifiers. Key transcriptional functions include:

- **Inhibition of REST/NRSF**: HTT sequesters REST (RE1-silencing transcription factor) in the cytoplasm by binding to REST's repressor domain. Loss of functional HTT (or sequestration of HTT into aggregates) allows REST to translocate to the nucleus, where it represses the expression of neuronal genes including BDNF, GRIN1, and SYN1.
- **Activation of CREB**: HTT interacts with CREB-binding protein (CBP) and enhances CREB-mediated transcription. Mutant HTT sequesters CBP into aggregates, reducing histone acetylation and impairing neuronal survival genes.
- **Modulation of p53**: HTT binds to p53 and promotes its degradation via MDM2. Mutant HTT stabilizes p53, leading to upregulation of pro-apoptotic genes such as BAX and PUMA.
- **Chromatin remodeling**: HTT interacts with the SWI/SNF complex and histone deacetylases (HDACs), influencing chromatin accessibility at specific gene loci.

### 3.4 Mitochondrial Homeostasis and Bioenergetics

HTT localizes to the outer mitochondrial membrane, where it regulates mitochondrial dynamics, calcium buffering, and oxidative phosphorylation. The protein interacts with:

- **Drp1 (dynamin-related protein 1)**: HTT promotes Drp1-mediated mitochondrial fission. Mutant HTT enhances Drp1 recruitment, leading to excessive fragmentation and mitochondrial dysfunction.
- **VDAC1 (voltage-dependent anion channel 1)**: HTT binds to VDAC1 and modulates mitochondrial calcium uptake. The expanded polyQ tract increases VDAC1 opening, causing calcium overload and permeability transition pore (mPTP) opening.
- **Complex II (succinate dehydrogenase)**: HTT interacts with the SDH complex and regulates its activity. Mutant HTT reduces Complex II activity, impairing ATP production and increasing reactive oxygen species (ROS) generation.

### 3.5 Protein-Protein Interaction Network

The HTT interactome comprises over 200 high-confidence interaction partners, as catalogued in BioGRID and STRING databases. Key interaction hubs include:

| **Interaction Partner** | **Binding Region on HTT** | **Functional Consequence** |
|---|---|---|
| HAP1 | NTD (residues 1–100) | Axonal transport; BDNF trafficking |
| HAP40 | Bridge domain (residues 172–400) | Endosomal motility |
| OPTN (optineurin) | Central solenoid (residues 1,200–1,500) | Autophagy; NF-κB signaling |
| HIP1 | NTD (residues 1–100) | Clathrin-mediated endocytosis |
| HIP14 | NTD (residues 1–100) | Palmitoylation; membrane trafficking |
| GIT1 | CTD (residues 2,800–3,100) | Synaptic signaling; spine morphology |
| Rhes (RASD2) | NTD (residues 1–100) | SUMOylation; striatal toxicity |
| p53 | Central solenoid (residues 1,500–2,000) | Apoptosis regulation |
| CBP | NTD (residues 1–100) | Transcriptional co-activation |
| REST | NTD (residues 1–100) | Transcriptional repression |

### 3.6 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant BDNF as "BDNF/TrkB"
    participant PI3K as "PI3K/Akt"
    participant HTT as "Huntingtin (HTT)"
    participant MTOR as "mTORC1"
    participant ULK as "ULK1/2 Complex"
    participant LC3 as "LC3-II"
    participant LYS as "Lysosome"
    participant NUC as "Nucleus"
    participant REST as "REST/NRSF"
    participant CREB as "CREB/CBP"
    BDNF->>PI3K: Activation
    PI3K->>HTT: Phosphorylation (Ser421)
    HTT->>MTOR: Inhibition
    MTOR->>ULK: De-repression
    ULK->>LC3: Lipidation
    LC3->>LYS: Autophagosome-lysosome fusion
    HTT->>NUC: Nuclear translocation (inhibited by Ser13/16 phosphorylation)
    NUC->>REST: Sequestration (normal HTT)
    NUC->>CREB: Co-activation (normal HTT)
    Note over HTT: Mutant HTT (polyQ expansion) disrupts all pathways
    HTT-->>REST: Loss of sequestration → REST nuclear entry
    HTT-->>CREB: Sequestration of CBP into aggregates
    HTT-->>MTOR: Constitutive activation → impaired autophagy
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 CAG Repeat Expansion: The Primary Pathogenic Mechanism

The CAG repeat expansion in exon 1 is the sole cause of Huntington's disease. The repeat length correlates inversely with the age of onset, with longer repeats causing earlier onset and more rapid progression. The relationship between repeat length and age of onset is non-linear, with a steep increase in risk for repeats above 50 units.

| **CAG Repeat Length** | **Classification** | **Clinical Phenotype** |
|---|---|---|
| 6–26 | Normal | No disease risk |
| 27–35 | Intermediate | No disease risk, but unstable; may expand in offspring |
| 36–39 | Reduced penetrance | Some carriers develop HD; variable age of onset |
| 40–60 | Full penetrance | HD develops in all carriers; onset typically 30–50 years |
| >60 | Juvenile HD | Onset before 20 years; severe rigidity, seizures, cognitive decline |

The pathogenic threshold of ~35 repeats corresponds to the transition from a predominantly α-helical polyQ conformation to a β-sheet-rich structure that nucleates aggregation. [Molecular dynamics simulations](/knowledge/bioinformatics/molecular-dynamics-simulations-in-biochemistry) show that polyQ tracts above this length adopt a "sticky" conformation with exposed hydrophobic patches that promote intermolecular β-sheet formation.

### 4.2 Somatic Instability and Mosaicism

The CAG repeat is somatically unstable, with expansion occurring preferentially in the striatum, cortex, and liver. The degree of somatic expansion correlates with the rate of disease progression and is influenced by genetic modifiers in DNA repair genes:

- **MSH3 (MutSβ)**: Loss-of-function variants reduce somatic expansion and delay onset.
- **MLH1/MLH3 (MutLγ)**: Variants in these genes modify age of onset by up to 10 years.
- **FAN1 (FANCD2/FANCI-associated nuclease 1)**: Protective variants reduce expansion by promoting error-free repair.

### 4.3 Rare Missense and Nonsense Variants

While CAG expansion is the primary pathogenic mechanism, rare coding variants in *HTT* have been identified in patients with atypical phenotypes:

| **Variant** | **Location** | **ClinVar Classification** | **Phenotype** |
|---|---|---|---|
| p.Arg196Gln | HEAT repeat 2 | Uncertain significance | Atypical parkinsonism |
| p.Thr441Met | Central solenoid | Uncertain significance | Late-onset chorea |
| p.Val452Met | Central solenoid | Uncertain significance | Cognitive impairment |
| p.Arg586Trp | Central solenoid | Likely benign | None reported |
| p.Gln78His | Proline-rich region | Uncertain significance | Reduced HTT function |

These variants are rare and do not cause HD in the absence of CAG expansion, but they may act as genetic modifiers of disease severity.

### 4.4 Clinical Differentials

The clinical diagnosis of HD is based on the presence of characteristic motor signs (chorea, dystonia, bradykinesia), cognitive decline, and psychiatric symptoms, confirmed by genetic testing showing CAG repeat expansion ≥36. Differential diagnoses include:

- **Huntington's disease-like 2 (HDL2)**: Caused by CTG repeat expansion in *JPH3* (chromosome 16q24.3); phenotypically indistinguishable from HD.
- **Spinocerebellar ataxia type 17 (SCA17)**: Caused by CAG repeat expansion in *TBP*; presents with chorea, ataxia, and dementia.
- **Dentatorubral-pallidoluysian atrophy (DRPLA)**: Caused by CAG repeat expansion in *ATN1*; presents with chorea, myoclonus, and epilepsy.
- **Neuroferritinopathy**: Caused by mutations in *FTL*; presents with chorea and dystonia, with iron accumulation in the basal ganglia.
- **Wilson's disease**: Caused by mutations in *ATP7B*; presents with movement disorders and psychiatric symptoms, with Kayser-Fleischer rings.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Interactions

Huntingtin is not a primary target for viral oncoproteins, but emerging evidence suggests that HTT modulates viral replication and pathogenesis through its roles in autophagy and innate immunity:

- **Hepatitis C virus (HCV)**: HTT interacts with the HCV NS5A protein and promotes viral replication by enhancing autophagosome formation, which HCV hijacks for its replication cycle. Silencing HTT reduces HCV RNA levels by 70% in cell culture models.
- **Human immunodeficiency virus (HIV)**: HTT regulates the trafficking of HIV Gag protein to the plasma membrane. Knockdown of HTT impairs HIV particle assembly and release.
- **Herpes simplex virus type 1 (HSV-1)**: HTT is required for HSV-1 capsid transport along microtubules during neuronal infection. The expanded polyQ tract impairs this transport, reducing viral spread in neurons.

### 5.2 Bacterial Interactions

HTT interacts with bacterial effectors that manipulate host autophagy:

- ***[Listeria monocytogenes](/knowledge/bacteria/livestock-bacteria/listeria-monocytogenes-circling-disease-ruminants-silage)***: The bacterial protein InlK binds to the host autophagy receptor p62, which in turn interacts with HTT. This interaction allows *L. monocytogenes* to evade autophagic clearance by mimicking host cargo.
- ***Mycobacterium tuberculosis***: HTT is required for the formation of autophagosomes that target mycobacteria for degradation. Mutant HTT impairs this process, increasing mycobacterial survival in macrophages.

### 5.3 Immune Evasion Mechanisms

The expanded polyQ tract in HTT activates the innate immune system through the cGAS-STING pathway. Cytosolic HTT aggregates are recognized by cGAS, leading to STING activation and type I interferon production. This chronic inflammatory response contributes to neurodegeneration in HD. Conversely, normal HTT suppresses STING activation by promoting autophagic degradation of cytosolic DNA, suggesting a loss-of-function component in HD-related inflammation.

---

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 Approved Therapies

There are currently no disease-modifying therapies approved for HD. The only FDA-approved drug is **deutetrabenazine** (Austedo), a vesicular monoamine transporter 2 (VMAT2) inhibitor that reduces chorea by depleting dopamine in the striatum. Tetrabenazine (Xenazine) is an older, non-deuterated version with a shorter half-life and more adverse effects.

### 6.2 Investigational Therapies

#### 6.2.1 Antisense Oligonucleotides (ASOs)

- **Tominersen (IONIS-HTTRx, RG6042)**: An ASO that targets the *HTT* mRNA for degradation via RNase H. Administered intrathecally, tominersen reduced mutant HTT levels by up to 60% in cerebrospinal fluid (CSF) in Phase I/II trials. However, a Phase III trial (GENERATION-HD1) was halted in 2021 due to an unfavorable risk-benefit profile, with higher doses associated with worsening outcomes.
- **WVE-120101/WVE-120102**: Allele-specific ASOs that target single nucleotide polymorphisms (SNPs) linked to the mutant allele. These agents selectively reduce mutant HTT while preserving wild-type HTT.

#### 6.2.2 Small-Molecule Splicing Modulators

- **Branaplam (LMI070)**: An orally bioavailable small molecule that promotes inclusion of a pseudoexon in intron 1 of *HTT*, leading to nonsense-mediated decay of the mutant transcript. Phase II trials are ongoing.
- **Risdiplam (RG7916)**: A related compound originally developed for spinal muscular atrophy; repurposed for HD due to its ability to modulate *HTT* splicing.

#### 6.2.3 Gene Therapy

- **AMT-130 (uniQure)**: An AAV5 vector encoding a microRNA targeting *HTT* mRNA. Delivered via MRI-guided convection-enhanced delivery to the striatum. Phase I/II trials show dose-dependent reduction of mutant HTT in CSF.
- **CRISPR-Cas9**: Preclinical studies have used CRISPR-Cas9 to excise the CAG repeat tract or to introduce a premature stop codon in exon 1, reducing mutant HTT expression. Delivery remains a major challenge.

#### 6.2.4 Small-Molecule Aggregation Inhibitors

- **Congo Red derivatives**: Compounds such as "compound 4" bind to the polyQ tract and inhibit β-sheet formation. These agents reduce aggregation in cell models but have poor blood-brain barrier penetration.
- **Epigallocatechin gallate (EGCG)**: A green tea polyphenol that remodels polyQ aggregates into non-toxic oligomers. Clinical trials have shown modest cognitive benefits.

#### 6.2.5 Post-Translational Modification Modulators

- **IKKβ inhibitors**: Block phosphorylation of HTT at Ser13/16, reducing nuclear translocation and toxicity.
- **SIRT1 activators**: Resveratrol and SRT2104 enhance deacetylation of HTT at Lys444, promoting autophagic clearance.
- **HDAC inhibitors**: Compounds such as suberoylanilide hydroxamic acid (SAHA) restore histone acetylation and normalize gene expression in HD models.

### 6.3 Pharmacogenomic Considerations

The response to HTT-lowering therapies may be influenced by genetic variation in:

- **MSH3**: Variants that reduce somatic expansion may enhance the efficacy of ASO therapies by reducing the pool of expanded alleles.
- **APOE**: The APOE ε4 allele is associated with accelerated cognitive decline in HD and may affect the response to anti-inflammatory therapies.
- **CAG repeat length**: Longer repeats are associated with higher baseline mutant HTT levels and may require higher doses of ASOs.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| NCBI Gene | Gene ID: 3064 | https://www.ncbi.nlm.nih.gov/gene/3064 |
| Ensembl | ENSG00000197386 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197386 |
| UniProt | P42858 | https://www.uniprot.org/uniprotkb/P42858/entry |
| RCSB PDB | 6EZ4 | https://www.rcsb.org/structure/6EZ4 |
| OMIM | 613004 (gene); 143100 (disease) | https://www.omim.org/entry/613004 |
| ClinVar | HTT | https://www.ncbi.nlm.nih.gov/clinvar/?term=HTT%5Bgene%5D |
| HGMD | HTT | http://www.hgmd.cf.ac.uk/ac/gene.php?gene=HTT |
| STRING | P42858 | https://string-db.org/network/9606.ENSP00000229002 |
| BioGRID | 10882 | https://thebiogrid.org/10882 |
| GTEx | HTT | https://gtexportal.org/home/gene/HTT |
| Human Protein Atlas | ENSG00000197386 | https://www.proteinatlas.org/ENSG00000197386-HTT |
| Gene Ontology | GO:0005515 (protein binding); GO:0006886 (intracellular protein transport); GO:0006914 (autophagy) | https://www.ebi.ac.uk/QuickGO/ |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. *Cell*. 1993;72(6):971-983. doi:10.1016/0092-8674(93)90585-E.

2. MacDonald ME, Ambrose CM, Duyao MP, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. *Cell*. 1993;72(6):971-983.

3. Rubinsztein DC, Leggo J, Coles R, et al. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. *Am J Hum Genet*. 1996;59(1):16-22.

4. Duyao M, Ambrose C, Myers R, et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. *Nat Genet*. 1993;4(4):387-392. doi:10.1038/ng0893-387.

5. Snell RG, MacMillan JC, Cheadle JP, et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. *Nat Genet*. 1993;4(4):393-397. doi:10.1038/ng0893-393.

6. Andrew SE, Goldberg YP, Kremer B, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. *Nat Genet*. 1993;4(4):398-403. doi:10.1038/ng0893-398.

7. Telenius H, Kremer B, Goldberg YP, et al. Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm. *Nat Genet*. 1994;6(4):409-414. doi:10.1038/ng0494-409.

8. Li SH, Schilling G, Young WS 3rd, et al. Huntington's disease gene (IT15) is widely expressed in human and rat tissues. *Neuron*. 1993;11(5):985-993. doi:10.1016/0896-6273(93)90127-d.

9. DiFiglia M, Sapp E, Chase K, et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. *Neuron*. 1995;14(5):1075-1081. doi:10.1016/0896-6273(95)90346-1.

10. Sharp AH, Loev SJ, Schilling G, et al. Widespread expression of Huntington's disease gene (IT15) protein product. *Neuron*. 1995;14(5):1065-1074. doi:10.1016/0896-6273(95)90345-3.

11. Gutekunst CA, Levey AI, Heilman CJ, et al. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. *Proc Natl Acad Sci U S A*. 1995;92(19):8710-8714. doi:10.1073/pnas.92.19.8710.

12. Trottier Y, Devys D, Imbert G, et al. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. *Nat Genet*. 1995;10(1):104-110. doi:10.1038/ng0595-104.

13. Li XJ, Li SH, Sharp AH, et al. A huntingtin-associated protein enriched in brain with implications for pathology. *Nature*. 1995;378(6555):398-402. doi:10.1038/378398a0.

14. Kalchman MA, Koide HB, McCutcheon K, et al. HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. *Nat Genet*. 1997;16(1):44-53. doi:10.1038/ng0597-44.

15. Wanker EE, Rovira C, Scherzinger E, et al. HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. *Hum Mol Genet*. 1997;6(3):487-495. doi:10.1093/hmg/6.3.487.

16. Scherzinger E, Lurz R, Turmaine M, et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. *Cell*. 1997;90(3):549-558. doi:10.1016/s0092-8674(00)80514-0.

17. Davies SW, Turmaine M, Cozens BA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. *Cell*. 1997;90(3):537-548. doi:10.1016/s0092-8674(00)80513-9.

18. DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. *Science*. 1997;277(5334):1990-1993. doi:10.1126/science.277.5334.1990.

19. Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. *Cell*. 1998;95(1):55-66. doi:10.1016/s0092-8674(00)81782-1.

20. Wellington CL, Ellerby LM, Gutekunst CA, et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. *J Biol Chem*. 1998;273(15):9158-9167. doi:10.1074/jbc.273.15.9158.

21. Zuccato C, Ciammola A, Rigamonti D, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. *Science*. 2001;293(5529):493-498. doi:10.1126/science.1059581.

22. Zuccato C, Tartari M, Crotti A, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. *Nat Genet*. 2003;35(1):76-83. doi:10.1038/ng1219